1. hypersensitivity to nicotinamide riboside (nr); 2. pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; 3. egfr \<15 ml/min/1.73 m2 as per the chronic kidney disease epidemiology collaboration equation at admission lab; 4. maintenance renal replacement therapy or initiation of renal replacement therapy before randomization 5. currently on nr or nicotinamide or vitamin b3 (niacin) supplementation (multivitamins are allowed); 6. concomitant cirrhosis of liver or acute liver failure; 7. any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; 8. individuals with kidney transplant; 9. individuals with blood platelet count \<100,000/microl

1. hypersensitivity to nicotinamide riboside (nr); 2. pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; 3. egfr \<15 ml/min/1.73 m2 as per the chronic kidney disease epidemiology collaboration equation at admission lab; 4. maintenance renal replacement therapy or initiation of renal replacement therapy before randomization 5. currently on nr or nicotinamide or vitamin b3 (niacin) supplementation (multivitamins are allowed); 6. concomitant cirrhosis of liver or acute liver failure; 7. any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; 8. individuals with kidney transplant; 9. individuals with blood platelet count \<100,000/microl

hypersensitivity to nicotinamide riboside (nr); pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; egfr <15 ml/min/1.73 m2 as per the chronic kidney disease epidemiology collaboration equation at admission lab; maintenance renal replacement therapy or initiation of renal replacement therapy before randomization currently on nr or nicotinamide or vitamin b3 (niacin) supplementation (multivitamins are allowed); concomitant cirrhosis of liver or acute liver failure; any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; individuals with kidney transplant; individuals with blood platelet count <100,000/microl

hypersensitivity to nicotinamide riboside (nr); pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; egfr <15 ml/min/1.73 m2 as per the chronic kidney disease epidemiology collaboration equation at admission lab; maintenance renal replacement therapy or initiation of renal replacement therapy before randomization currently on nr or nicotinamide or vitamin b3 (niacin) supplementation (multivitamins are allowed); concomitant cirrhosis of liver or acute liver failure; any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; individuals with kidney transplant; individuals with blood platelet count <100,000/microl

1. hypersensitivity to nicotinamide riboside (nr); 2. pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; 3. egfr <15 ml/min/1.73 m2 as per the chronic kidney disease epidemiology collaboration equation at admission lab; 4. maintenance renal replacement therapy or initiation of renal replacement therapy before randomization 5. currently on nr or nicotinamide or vitamin b3 (niacin) supplementation (multivitamins are allowed); 6. concomitant cirrhosis of liver or acute liver failure; 7. any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; 8. individuals with kidney transplant; 9. individuals with blood platelet count <100,000/microl

1. hypersensitivity to nicotinamide riboside (nr); 2. pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; 3. egfr <15 ml/min/1.73 m2 as per the chronic kidney disease epidemiology collaboration equation at admission lab; 4. maintenance renal replacement therapy or initiation of renal replacement therapy before randomization 5. currently on nr or nicotinamide or vitamin b3 (niacin) supplementation (multivitamins are allowed); 6. concomitant cirrhosis of liver or acute liver failure; 7. any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; 8. individuals with kidney transplant; 9. individuals with blood platelet count <100,000/microl